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Transthoracic contrast echocardiography (TTCE) followed by CT in patients testing positive with this technique are the recommended imaging methods in the last 2010 clinical guideline (9) . Nonetheless, positive TTCE findings are relatively common in patients with HHT (60% to 85% of patients tested) (3, 10, 11), whereas a much smaller percentage of between 21% and 52.3% actually show PAVMs on CT (12) . Therefore, adherence to clinical guideline recommendations would result in a large number of unwarranted CT studies, implying unnecessary radiation exposure and healthcare expenditure (2, (13) (14) (15) . The results of a previous study by our group (13) and those of other authors (10, 14, 16) have indicated that use of a system to grade the passage of contrast material on TTCE to estimate the size of pulmonary shunts is of value for selecting patients who should subsequently undergo CT evaluation. Two TTCE grading systems have been proposed: a 4-grade scale (10, 13, 17) and a 3-grade scale (7, 14, 16) . The main difference between the two options is that grades 3 and 4 in the 4-grade scale correspond to grade 3 in the 3-grade scale. At present, the indication for CT seems clear in patients showing moderate or extensive contrast passage using these scales (grades 2, 3, and 4). In patients with a pulmonary shunt grade 1, according to the work of Velthuis et al Gelofusine is reported to provide better opacification of the heart chambers than agitated saline solution (21), as the bubbles formed are smaller (22, 23) and more stable (24). Use of Gelofusine may result in a smaller number of suboptimal studies relative to saline contrast(21, 24).
Based on this background, the aim of this study was to assess the use of graded contrast echocardiography for selecting Spanish HHT patients to undergo CT, and evaluate the performance of agitated saline solution versus Gelofusine as contrast media. To the best of our knowledge, this is the first study comparing these two contrast agents in the screening of PAVMs of HHT patients.
Materials and Methods
From January 2003 to December 2014, 664 patients with suspected HHT were seen in our HHT unit through one of the following channels: ambulatory visit, hospital admittance, or genetic testing alone. Patients seen through either of the first 2 channels underwent a hospital protocol that included a clinical historytaking, physical examination, laboratory testing, genetic testing, TTCE, chest or abdominal CT, abdominal ultrasound, and brain or lumbar MRI, when clinically justified. Only patients who underwent TTCE and CT within an interval of ≤180 days between the two techniques were included in the study. Patients in whom a persistent foramen ovale was detected were excluded. The hospital ethics committee for clinical research of the Autonomous Community of Cantabria 9 approved the study protocol. All patients provided written consent for participation. The presence or absence of anemia was considered in women and men when hemoglobin (Hb) levels were lower than 12 g/dL, and 13,5 g/dL, respectively The TTCE technique, previously used by our team and described by others (13, 14) , was performed by 3 experienced echocardiographers, following intravenous line placement in an antecubital vein. The two contrast agents, agitated saline (9 ml saline solution mixed with 0.5 ml room air and 0.5 ml of blood from the patient) and Gelofusine (10 ml), were administered with the patient in left lateral decubitus. A four-chamber view was used, and TTCE was considered positive for pulmonary shunting when bubbles were observed in the left atrium without application of the Valsalva maneuver. The number of cardiac cycles that occurred before bubbles appeared in the left atrium was recorded and a delay of >3 cycles was established to differentiate PAVMs from intracardiac shunt (25). Shunts visualized through a pulmonary vein were classified as pulmonary shunts regardless of the cardiac cycle (12) . A second study with Valsalva manoeuvre was performed when contrast was present in the left atrium in less than four cardiac and 2014, patients additionally underwent TTCE using Gelofusine to determine whether there were differences in screening outcomes versus saline. The same protocol described above was used, and the Gelofusine study was performed a few minutes after the saline study in the same session after making sure that there were no bubbles from the previous study.
Chest CT was carried out on 3 different multidetector systems over the study period: a 2-row Somaton AR.T scanner (Siemens, Erlangen, Germany), a 32-row LightSpeed scanner (General Electric, New York, USA), and an 80-row Aquilion Prime TSX-303A scanner (Toshiba Medical Systems Corporation, Japan), using≤3 mm slice thickness (9) . Nonionic contrast agent (300 mg/mL iodine at a rate of 3 mL/sec and maximum dose of 2 mL/kg) was routinely administered because in most of these patients the liver was included in the study in order to rule out hepatic arteriovenous malformations (HAVMs). These studies were performed in a caudo-craneal direction and always included an image acquisition in an early arterial phase (5, 26) . The images obtained were evaluated by 3 radiologists with experience in HHT. Visualization of a nodule with an afferent artery and efferent vein was considered diagnostic for PAVM (5) . The presence of telangiectases, perfusion disorders, vascular confluent masses or arteriovenous or veno-venous shunts were considered diagnostic for HAVMs (27). In the assessments of TTCE and CT features, readers were blinded to the results of the other imaging study.
Revascularization of a previously treated PAVM was defined based on CT findings of a persistent aneurysmal sac with prominent afferent arteries and drainage veins 11 (28, 29). Patients with an afferent artery measuring ≥3mm, a PAVM with less size but suitable for embolization and those with CT criteria indicating revascularization (30) were sent to the angiography suite to plan embolotherapy.
Statistical analysis
Baseline characteristics of the patients were compared using a Mann-Whitney U 
Results
Of the 664 patients evaluated in the HHT Unit of Hospital Sierrallana (Cantabria, Spain), 449 (65.2%) were diagnosed with HHT based on clinical criteria or genetic testing. Among this total, 312 (69.5%) patients had TTCE to rule out PAVMs, and 12 assessments of 14 days (SD 34.8, range 0-180 days). There were no significant differences in demographic and genetic characteristics between the overall population and those undergoing the two imaging assessments (Table 1) . Ninetyfive of these 205 patients had been included in a previous study (13) .
The demographic characteristics of the 205 patients who underwent TTCE and CT stratified by TTCE grade are shown in Table 2 . Patients in higher grades were significantly younger than those TTCE negative or in lower grades (p=0.04). Fifty-nine (38.8%) of 152 TTCE-positive patients had a PAVM on CT (Table 3) One patient categorized as TTCE-negative (no passage of contrast visualized) had a previously embolized PAVM showing no signs of revascularization on CT. Twentyfour patients had a single PAVM and 35 (59.3%) multiple PAVMs, with no significant differences in the incidence of single or multiple PAVMs between 13 grades. However a trend was detected in which the higher the grade, the greater the probability of having multiple PAVMs (test for trend: P=0.10).
Among 152 TTCE positive patients, the cardiac cycle at which microbubbles first appeared in the left heart chambers after contrast administration was recorded in 137 patients. The mean cardiac cycle at visualization of bubbles in the left ventricle was 6.6 in grade 1, 4.7 in grade 2, 4 in grade 3, and 3.2 in grade 4 ( Table   4 ). In patients classified into higher grades, contrast bubbles appeared earlier (p<0.0001), such that in grade 4, 61.9% of patients showed bubbles in the left atrium during the third cardiac cycle.
In patients without PAVM on CT, bubbles were first seen in the left heart chambers at a mean of 6.1cardiac cycles (SD 1.7) and 3.9 (SD 0.1) in those with PAVM on CT (p<0.0001) ( In the comparative study, 114 patients underwent TTCE using the 2 contrast agents ( Table 7) . As compared to saline TTCE, Gelofusine TTCE resulted in 
Discussion
Several findings from the present study are consistent with those of our previous research (13) and the results of other authors (7, 10, 14, 16) . The data further support the idea that although small PAVMs can be detected on contrast TTCE (grade 1), the afferent artery is not large enough to undergo embolotherapy, and therefore, CT would not be needed (7, 13, 14) . Analysis of the situation regarding TTCE grade 2 requires special consideration. In patients classified as grade 2, some treatable PAVMs are detected and CT would be indicated in these cases.
Nonetheless, the percentage of PAVMs ultimately identified by CT is low: only 25%
to 45.3% of these patients (42.9% in this series) have a PAVM on CT (10, 13, 14).
Furthermore, the percentage amenable to embolotherapy is even lower: 16.7% in this series and 25.3% in the study of Velthuis et al (14) . Thus, more than half the patients rated as TTCE grade 2 using the current criteria would actually not need CT evaluation. Hence, it would be of value to further refine the criteria to differentiate between TTCE grades 1 and 2 to reduce the number of unnecessary CTs in these patients.
Without a doubt, CT is needed to characterize the malformation in patients in TTCE grades 3 and 4 (13, 14) . More than 75% of these patients (77.3% in our series, 77.4% in the series of Velthuis et al. (14) have PAVM on CT and more than 80% are accessible to embolotherapy (82.2% in grade 3 and 95% in grade 4 in our study and 83.7% in the study of Velthuis et al) (14) Previous reports found a relationship between TTCE grade and HHT genotype (7, 14) and our results concur with these findings: HHT2 predominated in TTCEnegative patients and grade 1, whereas HHT1 predominated in the remaining grades. Velthuis et al (14) reported no differences in age or sex between patients categorized into the different grades, but in our series, patients with higher grades were significantly younger than those in the lower grades. These findings support the notion that lung involvement is more frequent and more severe in patients with the HHT1 subtype, as described (7, 31) . Female predominate in the study group although there was a slight predominance of men in grade 4. Further studies in larger samples are needed to determine whether these are generalizable differences or result from a collateral effect of the sample. The number of patients with multiple PAVMs (60%) was similar to previously reported values (32).
Reduced oxygenation of blood due to pulmonary PAVMS, anemia and/or the presence of HAVMs could in HHT patients increased cardiac output as reported (8, 32 ). An increase in cardiac output has been shown to lead to an increase of blood flow through normally present intrapulmonary arteriovenous anastomosis and therefore be the cause of false positive TTCE results in HHT patients (20).
However, in our study, patients testing negative for TTCE had similar levels of Hb and HAVMs to those with positive TTCE results; suggesting that these parameters do not significantly affect the TTCE findings.
With regard to the cardiac cycle time point, our current results confirm those of our previous study (13) : contrast passage occurred earlier in higher grades.
Furthermore, and in contrast to the results of Zukotynski et al (10), we found a statistically significant difference in the cardiac cycle at which bubbles were first seen in the left chambers on TTCE between patients with and without PAVMs on 17 CT (p<0.0001). The fourth cycle seemed to be the best cut-off for this purpose, yielding a sensitivity of 81.5% and specificity of 71.5%, and correctly diagnosing 79% of patients. However, we were unable to establish a useful cardiac cycle to differentiate between patients with and without CT-confirmed PAVMs within each TTCE grade. Studies in larger patient samples may clarify this aspect.
The treatment of choice for PAVMs is currently embolotherapy, a technique that has minimal functional repercussions and relatively low invasiveness (34, 35).
Sixteen patients had previously undergone embolotherapy of one or several PAVMs when they were first seen in our unit. Forty-one patients showed PAVMs on CT with afferent arteries large enough to be treated at follow-up (35); most were in grades 3 and 4 and embolotherapy was feasible in more than 82%. These results concur with those of Velthuis et al (14):
83.7% of their grade 3 patients had embolotherapy.
To our knowledge, this is the first study comparing contrast TTCE using agitated saline versus Gelofusine for PAVM screening in an HHT population. In all TTCE grades, there was a clear trend to categorize patients into a higher grade with use of Gelofusine than with saline. We attribute this to the smaller size of the Gelofusine bubble, although other characteristics of this contrast medium, such as more stable bubbles and longer bubble retention (21, 24), may contribute to this difference. Of particular note, a number of patients classified as TTCE-negative using saline were passed to grade 1 or even 2 with Gelofusine. We cannot say whether this is attributable to a greater capacity of Gelofusine to detect small PAVMs or simply false-positive detection. Small pulmonary shunts on TTCE have with the use of either contrast agent in our study.
One limitation of this study is that 2-detector CT was used in some examinations.
More sensitive systems would likely detect a larger number of small PAVMS, and this may justify the low incidence of PAVMs in our grade 1 group relative to other studies (7, 14) . However, we believe that this limitation does not significantly influence the interpretation of the results, as detection of significant PAVMs would not be affected. Second, semiquantitative measurement was used to differentiate between grades 2 and 3, and 3 and 4, although the results were comparable to those found in a study using a quantitative cut-off (14) . Third, patients who had undergone previous PAVM embolization were not excluded because in clinical practice, TTCE findings of grade 2 to 4 PAVM in these patients indicate the need for CT assessment of possible revascularization.
In summary, the results of this study further support our previous interpretation that CT is not needed in patients with grade-1 shunt on TTCE. We believe that the definition of grade 2 should be refined to better differentiate between grades 1 and LR, likelihood ratio. 
